Publications

Leonard Appleman, MD, PhD

Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT. Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. Cancer J. 2019 May/Jun;25(3):165-177. doi: 10.1097/PPO.0000000000000374. PubMed PMID: 31135523.
Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer. 2019 Jun;17(3):e447-e453. doi: 10.1016/j.clgc.2019.01.005. PubMed PMID: 30799129.
Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, Onorati A, Kalavacharla A, Kim T, Zhen CJ, Kadri S, Segal JP, Gimotty PA, Davis LE, Amaravadi RK. Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clin Cancer Res. 2019 Apr 1;25(7):2080-2087. doi: 10.1158/1078-0432.CCR-18-2204. PubMed PMID: 30635337.
Hugar LA, Yabes JG, Turner RM 2nd, Fam MM, Appleman LJ, Davies BJ, Jacobs BL. Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis. Urology. 2019 Feb;124191-197. doi: 10.1016/j.urology.2018.11.001. PubMed PMID: 30423302.
Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9. PubMed PMID: 29378660; PMCID: PMC5789686.
Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018 Mar 10;36(8):765-772. doi: 10.1200/JCO.2017.74.7352. PubMed PMID: 29309249.
Achkar T, Arjunan A, Wang H, Saul M, Davar D, Appleman LJ, Friedland D, Parikh RA. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features. PLoS One. 2017;12(12):e0190084. doi: 10.1371/journal.pone.0190084. PubMed PMID: 29261796; PMCID: PMC5738119.
Lontos K, Tsagianni A, Msaouel P, Appleman LJ, Nasioudis D. Primary Urinary Tract Lymphoma: Rare but Aggressive. Anticancer Res. 2017 Dec;37(12):6989-6995. doi: 10.21873/anticanres.12167. PubMed PMID: 29187485; PMCID: PMC5726395.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Phase I study of veliparib in combination with gemcitabine. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. PubMed PMID: 28770300; PMCID: PMC5734661.
Appleman LJ, Maranchie JK. Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions. Urol Oncol. 2018 Jan;36(1):17-22. doi: 10.1016/j.urolonc.2017.06.005. PubMed PMID: 28736252.
Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS. A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer. 2017 Dec;15(6):642-651.e1. doi: 10.1016/j.clgc.2017.04.023. PubMed PMID: 28545998; PMCID: PMC5675826.
de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. PubMed PMID: 28220024; PMCID: PMC5344647.
Kim KP, Parise RA, Holleran JL, Lewis LD, Appleman L, van Erp N, Morris MJ, Beumer JH. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2017 May 10;138197-205. doi: 10.1016/j.jpba.2017.02.018. PubMed PMID: 28219796; PMCID: PMC5357460.
Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. PubMed PMID: 27169994; PMCID: PMC5106340.
Nguyen NC, Shah M, Appleman LJ, Parikh R, Mountz JM. Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation. Int J Mol Imaging. 2016;20162568031. doi: 10.1155/2016/2568031. PubMed PMID: 27774318; PMCID: PMC5059539.
de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunol Res. 2016 Oct;4(10):820-822. doi: 10.1158/2326-6066.CIR-16-0110. PubMed PMID: 27538576; PMCID: PMC5050137.
Parikh RA, Appleman LJ, Beumer JH, Matczak E, Chu E. Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features. Clin Genitourin Cancer. 2017 Feb;15(1):7-22. doi: 10.1016/j.clgc.2016.05.011. PubMed PMID: 27473523.
Mehta K, Appleman L, Wang H, Tarhini AA, Parikh RA. Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients. PLoS One. 2016;11(1):e0147153. doi: 10.1371/journal.pone.0147153. PubMed PMID: 26799322; PMCID: PMC4723120.
Amjad AI, Parikh RA, Appleman LJ, Hahm ER, Singh K, Singh SV. Broccoli-Derived Sulforaphane and Chemoprevention of Prostate Cancer: From Bench to Bedside. Curr Pharmacol Rep. 2015 Nov 1;1(6):382-390. doi: 10.1007/s40495-015-0034-x. PubMed PMID: 26557472; PMCID: PMC4635516.
Amjad AI, Ali H, Appleman LJ, Maranchie J, Jackman S, Parwani A, Dhir R, Roy S, Parikh RA. Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy. Case Rep Oncol Med. 2014;2014615895. doi: 10.1155/2014/615895. PubMed PMID: 25215253; PMCID: PMC4156985.
Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 2014;7969-83. doi: 10.2147/OTT.S40241. PubMed PMID: 24959084; PMCID: PMC4061161.
Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94. doi: 10.1200/JCO.2013.52.4785. PubMed PMID: 24821883.

<< Investigators Search

Top